Overall prognosis of preschool autism spectrum disorder diagnoses (Protocol)

Brignell A, Albein-Urios N, Woolfenden S, Hayen A, Iorio A, Williams K


www.cochranelibrary.com
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEADER</td>
<td>1</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>1</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>1</td>
</tr>
<tr>
<td>OBJECTIVES</td>
<td>4</td>
</tr>
<tr>
<td>METHODS</td>
<td>4</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>8</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>8</td>
</tr>
<tr>
<td>APPENDICES</td>
<td>11</td>
</tr>
<tr>
<td>WHAT’S NEW</td>
<td>16</td>
</tr>
<tr>
<td>CONTRIBUTIONS OF AUTHORS</td>
<td>17</td>
</tr>
<tr>
<td>DECLARATIONS OF INTEREST</td>
<td>17</td>
</tr>
<tr>
<td>SOURCES OF SUPPORT</td>
<td>17</td>
</tr>
</tbody>
</table>
**Overall prognosis of preschool autism spectrum disorder diagnoses**

Amanda Brignell¹, Natalia Albein-Urios², Susan Woolfenden³,⁴, Andrew Hayen⁵, Alfonso Iorio⁶, Katrina Williams¹,⁷,⁸

¹Murdoch Childrens Research Institute, Parkville, Australia. ²Deakin Child Study Centre, School of Psychology, Deakin University, Geelong, Australia. ³Sydney Children’s Hospital Network, Randwick, Australia. ⁴School of Women’s & Children’s Health, UNSW Sydney, Randwick, Australia. ⁵Australian Centre for Public and Population Health, Faculty of Health, University of Technology Sydney, Sydney, Australia. ⁶Department of Health Research Methods, Evidence and Impact (HEI), McMaster University, Hamilton, Canada. ⁷Department of Paediatrics, The University of Melbourne, Parkville, Australia. ⁸Department of Neurodevelopment & Disability, The Royal Children’s Hospital, Parkville, Australia

Contact address: Amanda Brignell, Murdoch Childrens Research Institute, 50 Flemington Road, Parkville, Victoria, 3052, Australia. amanda.brignell@mcri.edu.au, a_brignell@yahoo.com.au.

**Editorial group:** Cochrane Developmental, Psychosocial and Learning Problems Group.

**Publication status and date:** Edited (no change to conclusions), published in Issue 8, 2017.


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**ABSTRACT**

This is a protocol for a Cochrane Review (Prognosis). The objectives are as follows:

The primary objective of this review is to synthesise the available evidence on the proportion of individuals who have a diagnosis of autism spectrum disorder at baseline and at follow-up one or more years later.

The secondary objectives of this review are to:

1. investigate whether there are differences in the proportions of individuals with autism spectrum disorder who maintain a diagnosis at follow-up dependent on use of the different classification systems (i.e. DSM or ICD criteria) and their revisions; and

2. investigate the proportion of individuals with autism spectrum disorder who maintain diagnosis at follow-up in important subgroups of individuals, including those of different ages and those with different language levels (verbal/non-verbal; standard score ≤ 70 or > 70), IQs (≤ 70 or > 70), adaptive behaviour (standard score ≤ 70 or > 70), and different diagnostic subgroups (Asperger’s syndrome/disorder, autistic disorder, childhood autism, PDD-NOS, atypical autism, PDD and autism spectrum disorder).

We will investigate potential sources of heterogeneity that may impact outcomes such as differences in study participation, study design, length of follow-up, participant attrition and participant outcome measurement factors. We will use internationally recognised standards for systematic reviews to guide the review.

**BACKGROUND**

Autism spectrum disorder is a complex and heterogeneous neu-
redevelopmental disorder. It is currently diagnosed by the presence of two core features, which include social communication difficulties, and repetitive and restricted interests and behaviours (APA 2013). A diagnosis of autism spectrum disorder is typically made using criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM) or the International Classification of Diseases (ICD) (APA 2013; WHO 1992). A number of other neurodevelopmental conditions are associated with autism spectrum disorder, such as speech and language difficulties, intellectual disability, and attention deficit hyperactivity disorder. In the fifth edition of the DSM (DSM-5) (APA 2013), clinicians are encouraged to identify whether individuals have these aforementioned conditions, in addition to autism spectrum disorder. Severity ratings have also been introduced for each of the two main criteria (i.e. social communication difficulties and restricted and repetitive interests and behaviours), which form the diagnosis of autism spectrum disorder.

In the past two decades there have been many changes in the way individuals with autism spectrum disorder are diagnosed and cared for. While the DSM-5, published in 2013, now uses the broad term ‘autism spectrum disorder’ (APA 2013), previous editions of the DSM and the ICD have used different criteria and included diagnostic subgroups based on the individual’s profile of symptoms (APA 1980; APA 1994; APA 2000; NCHS 2011) (Table 1).

Table 1. Changes to the classification systems over time.

<table>
<thead>
<tr>
<th>Classification system</th>
<th>Year published</th>
<th>Subgroups (as specified in the classification system)</th>
</tr>
</thead>
<tbody>
<tr>
<td>International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)</td>
<td>1975</td>
<td>Autistic disorder</td>
</tr>
<tr>
<td>International Classification of Diseases, Tenth Revision (ICD-10)</td>
<td>1996</td>
<td>Childhood autism, Asperger’s syndrome, atypical autism, pervasive developmental disorder (PDD - unspecified)</td>
</tr>
<tr>
<td>Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III)</td>
<td>1980</td>
<td>PDD: infantile autism, childhood onset PDD and atypical PDD</td>
</tr>
<tr>
<td>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)</td>
<td>1994 to 2000</td>
<td>Asperger’s disorder, autistic disorder, PDD-NOS</td>
</tr>
<tr>
<td>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)</td>
<td>2000 to 2013</td>
<td>Asperger’s disorder, autistic disorder, PDD-NOS</td>
</tr>
<tr>
<td>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)</td>
<td>2013 to current</td>
<td>Autism spectrum disorder</td>
</tr>
</tbody>
</table>

Recently, the US National Institute of Mental Health has reoriented its focus away from diagnostic categories in mental disorders toward use of the Research Domain Criteria (RDoC) framework. This research framework focuses on the dimensions of functioning that underlie human behaviour. This reorientation will not impact already published studies that have used autism spectrum disorder diagnostic labels but may impact the way future studies are structured and the types of outcomes they report on, particularly those studies conducted in the USA.

The diagnostic validity of autism spectrum disorder, both in terms of its diagnostic accuracy and clinical utility, is not well described despite the high prevalence of the disorder (CDC 2014; Kim 2011). Current recommendations on how autism spectrum dis-
order should be diagnosed include a combination of history, observation and application of DSM or ICD criteria, taking into account the overall abilities of the person and ensuring alternative diagnoses are excluded (NICE 2011; Volkmar 2014; WAADF 2012). A number of assessment tools have been published that can assist with diagnosis. These include the Autism Diagnostic Observation Schedule (ADOS; Lord 2000), the Autism Diagnostic Interview - Revised (ADI-R; Le Couteur 2003) and the Childhood Autism Rating Scale (CARS; Schopler 1980). It is recommended that input from a medical expert, psychologist and speech pathologist is available, and that other expertise may be required depending on the strengths and difficulties of each individual. In both practice and research, diagnostic process often falls short of this recommendation, and is instead based on clinical best estimates and the results of one or more diagnostic instruments. Unfortunately, all methods of diagnosing autism spectrum disorder include an unquantifiable amount of diagnostic inaccuracy, with a higher amount expected for practices that fall short of the current recommendations. As such, the diagnostic stability and long-term outcome of autism spectrum disorder are entangled and not yet able to be disentangled.

The clinical pathway for individuals with autism spectrum disorder can be variable, with some individuals showing signs of autism spectrum disorder from as early as 12 months of age and others being described as having typical development followed by a period of developmental regression or loss of previously acquired skills (Landa 2013). To receive a diagnosis of autism spectrum disorder, symptoms must be present from childhood; however, some individuals with more subtle functional impairment may not receive a diagnosis of autism spectrum disorder until the school years or adulthood. The reported prevalence of autism spectrum disorder has increased over the past two decades (Elsabbagh 2012), with estimates from the USA reporting that 1.5% of children aged eight years have been diagnosed with the condition (CDC 2014). Elsabbagh 2012 reported the global median of prevalence estimates of autism spectrum disorders to be 62/10,000 (range 0.01% to 1.89%). Several factors have been proposed that may have had an impact on the increase in prevalence of autism spectrum disorder, including increased community awareness of the condition, administrative factors (e.g. specific funding for a diagnosis of autism spectrum disorder relative to other conditions), a broadening of the criteria used to diagnose autism spectrum disorder and diagnostic substitution with conditions such as intellectual disability (Fombonne 2009; Hansen 2015; King 2009; Wing 2002a). A study from Sweden reported an increase in the diagnosis of autism spectrum disorder but no change in the prevalence of traits of the type seen with autism spectrum disorder (Lundstrom 2015). Whether there is a true increase in autism spectrum disorder, or whether the increase in the prevalence of the disorder is due to the aforementioned factors, is yet to be determined.

The cause of autism spectrum disorder is not yet known although it is thought to have roots in genetics and brain development. Autism spectrum disorder may have shared aetiological pathways with other neurodevelopmental disabilities, such as intellectual disability, language impairment and attention deficit hyperactivity disorder, and individuals with these conditions may present with overlaps in functioning, behaviour and cognitive deficits (Simonoff 2008). The aforementioned conditions commonly co-occur with autism spectrum disorder and may exacerbate the symptoms of autism spectrum disorder. No biological markers for autism spectrum disorder have been identified; hence, autism spectrum disorder is diagnosed by behavioural observation.

Many clinicians and families believe that autism spectrum disorder is a lifelong disability; however, there is debate in the current literature regarding the permanence of autism spectrum disorder. Some studies have reported that a significant proportion of previously affected individuals no longer meet the diagnostic criteria for the disorder (Corsello 2013; Daniels 2011; Kleinman 2008; Turner 2007), and have also reported a variety of factors found to influence the stability of the diagnosis. These factors included: age at diagnosis (Daniels 2011; Turner 2007); milder symptoms of autism spectrum disorder (particularly in the social domain) and higher cognitive scores at two years of age (Turner 2007); the diagnosing clinician, region and a history of regression (Daniels 2011); and maturation, type of diagnosis (autistic disorder versus pervasive developmental disorder (PDD) - not otherwise specified (NOS)), amount of intervention and over-diagnosis at two years of age (Kleinman 2008). Other studies report that autism spectrum disorder can be reliably diagnosed and that few individuals “grow out” of a diagnosis (Barbaro 2016; Guthrie 2013; Jónsdóttir 2007; Ozonoff 2015; Takeda 2005). In early intervention studies, if children no longer fulfil the criteria for autism spectrum disorder at the end of the study, they may be described as having achieved an “optimal outcome” (e.g. Fein 2013; Orinstein 2014).

Individuals are diagnosed with autism spectrum disorder at varying ages and following different early life experiences. The diagnosis conveys problems with an individual’s ability and implies that they may face challenges ahead that will require intervention and support in addition to that required by their peers. These challenges might include difficulty with social relationships, poor reading, spelling and communication abilities, behaviour difficulties, higher levels of dependence on others and a poorer quality of life (Howlin 2004; Howlin 2012). The steps that then follow depend on the individual’s problems and abilities, the parents’ or individual’s wishes, available and accessible interventions and services, and the trajectory from the time of diagnosis. For example, families may choose to pursue a range of different interventions, from complementary to traditional, and their choices may be influenced by what is readily available or promoted in their community (Goin-Kochel 2007; Green 2006). What is currently lacking is an evidence base to inform the advice given to parents about what this diagnosis will mean for their child in the short and long term. In part, this is due to inconsistent evidence about the pro-
portion of individuals diagnosed with autism spectrum disorder who still fulfil the diagnosis after a year or more, and whether age at diagnosis, and different diagnostic subgroups and subgroups with different intelligence have different prognoses.

Why it is important to do this review

Autism spectrum disorder is a global health issue with far-reaching impacts for affected individuals, their families and support agencies. Substantial economic and social costs are associated with autism spectrum disorder (Ganz 2007; Horlin 2014), with the cost of supporting an individual with autism spectrum disorder throughout their lifespan estimated to be around US $2.4 million (if they have an intellectual disability) or US $1.4 million (without an intellectual disability) (Beuscher 2014). As such, there are substantial implications for policy makers and service providers with regard to the allocation of resources and the planning of future support needs of individuals with autism spectrum disorder. Families, individuals with autism spectrum disorder and clinicians require high-quality, reliable information about what proportion of individuals will continue to have a diagnosis of autism spectrum disorder as a crucial first step in understanding diagnostic validity and prognosis. It is also a vital part of the information that people need as they try to understand their own or their child’s strengths and difficulties, and plan for their short- and long-term future. Furthermore, information on the proportion of individuals who retain a diagnosis is important for policy makers and service providers so they can better plan future support needs for individuals.

A review that included a meta-analysis of eight longitudinal studies found that the proportion of children who were still diagnosed with an autism spectrum disorder at follow-up was lower if their original diagnosis was PDD-NOS rather than autistic disorder (Rondeau 2010). This study had a number of methodological limitations, such as only searching one database, and it did not assess risk of bias. Another review, Woollenden 2012, found that a substantial proportion of children diagnosed with PDD-NOS either did not have a diagnosis at follow-up or were diagnosed as having autistic disorder. The proportion that changed diagnosis was higher than many clinicians had anticipated. Variations in the persistence of a diagnosis according to age group, diagnostic subgroup and intelligence quotient (IQ) were also reported. Most studies included in the review were found to be at high risk of bias. Much work has been published since the time of the last searches for these prior reviews. An update is needed to find whether high-quality evidence is now available and to assess whether current information about the proportion of individuals who retain a diagnosis of an autism spectrum disorder at follow-up is sufficient to inform individually tailored decision making. This Cochrane Review will search a broader range of databases than previous reviews. It will also include a ’Risk of bias’ assessment of the included studies.

In this Cochrane Review, we will not be able to definitively determine whether the individual has ’grown out’ of autism spectrum disorder due to maturation or intervention, or if the original diagnosis was inaccurate. We will include studies in which diagnostic practices reflect current commonly used standards for research or clinical care and, if possible, we will investigate whether the diagnostic approach or tools (including age- or ability-modified versions of those tools), or both, at baseline, and consistency between tools at baseline and follow-up, contribute to differences in the proportions of children who retain a diagnosis. This will provide valuable information for clinicians and families about what the outcome will be in an individual with autism spectrum disorder one year or more after the use of these approaches.

OBJECTIVES

The primary objective of this review is to synthesise the available evidence on the proportion of individuals who have a diagnosis of autism spectrum disorder at baseline and at follow-up one or more years later.

The secondary objectives of this review are to:

1. investigate whether there are differences in the proportions of individuals with autism spectrum disorder who maintain a diagnosis at follow-up dependent on use of the different classification systems (i.e. DSM or ICD criteria) and their revisions; and

2. investigate the proportion of individuals with autism spectrum disorder who maintain diagnosis at follow-up in important subgroups of individuals, including those of different ages and those with different language levels (verbal/non-verbal; standard score ≤ 70 or > 70), IQs (≤ 70 or > 70), adaptive behaviour (standard score ≤ 70 or > 70), and different diagnostic subgroups (Asperger's syndrome/disorder, autistic disorder, childhood autism, PDD-NOS, atypical autism, PDD and autism spectrum disorder).

We will investigate potential sources of heterogeneity that may impact outcomes such as differences in study participation, study design, length of follow-up, participant attrition and participant outcome measurement factors. We will use internationally recognised standards for systematic reviews to guide the review.

METHODS

Criteria for considering studies for this review

Overall prognosis of preschool autism spectrum disorder diagnoses (Protocol)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Types of studies
We will include published reports of prospective and retrospective longitudinal studies investigating the prognosis of autism spectrum disorder that use the same measure to diagnose autism spectrum disorder at baseline and follow-up. Studies are required to have at least 12 months of follow-up and contain at least 10 participants. The decision to use 10 as the minimum number of participants was made in conjunction with a statistician and is consistent with prior methods used in other studies (e.g. Magiati 2014). A study may or may not include a comparison group that is being observed over the same time period, the characteristics of which are being assessed in the same manner. We will exclude studies from the review if the follow-up of children or adults with autism spectrum disorder is incidental to another syndrome and the outcomes are not appropriately measured (i.e. information on diagnosis at follow-up is not provided).

Types of participants
Participants diagnosed with autism spectrum disorder, PDD, PDD-NOS, atypical autism, PDD-unspecified, Asperger’s syndrome/disorder, autism, autistic disorder or childhood autism. Diagnosis must have been made using a standardised diagnostic tool (see “Types of outcome measures” below for eligible tools) or by using established diagnostic criteria (e.g. criteria from the third edition (APA 1980), fourth edition (APA 1994), fourth edition, text revision (APA 2000) and fifth edition (APA 2013) of the DSM (DSM-III, DSM-IV, DSM-IV-TR and DSM-5, respectively), or the ninth revision (WHO 1979) and tenth revision (WHO 1992) of the ICD (ICD-9 and ICD-10, respectively). Only children initially diagnosed before the aged of six years and followed up before the age of 19 years will be eligible for inclusion. We will include children with a dual diagnosis; for example, a diagnosis of Asperger’s syndrome/disorder and attention deficit hyperactivity disorder. We will include children with medical aetiologies such as Fragile X syndrome and tuberous sclerosis only if these medical conditions co-occur with a diagnosis of autism spectrum disorder and occur infrequently within the sample, rather than being the focus of the sample. We will exclude studies of children who have Rett syndrome.

Types of prognostic factors
We will not be analysing prognostic factors in this review.

Types of outcome measures
This review will focus on diagnostic stability only. There are other important outcomes for individuals with autism spectrum disorder (e.g. adaptive behaviour); however, reporting on these is beyond the scope of this review.

Primary outcome
1. Proportion of individuals who have a diagnosis of autism spectrum disorder at baseline and at follow-up one or more years later.
   Diagnosis at follow-up must have been made using DSM or ICD criteria, or a DSM- or ICD-compatible standardised tool. Tools accepted for diagnosis include: the ADI-R (Le Couteur 2003), CARS (Schopler 1980), ADOS (Lord 2000), Diagnostic Interview for Social and Communication Disorders (DISCO; Wing 2002b), the Gilliam Autism Rating Scale (GARS; Gilliam 1995) and the Developmental, Dimensional and Diagnostic Interview (3di; Skuse 2004). For each tool, individuals must meet the published cut-off for a diagnosis of autism spectrum disorder. We expect that most studies will present this outcome as a dichotomous variable (i.e. diagnosis or no diagnosis). For studies that present data using continuous measures (e.g. a score on a diagnostic scale), we will analyse the data by computing a dichotomous variable. If studies do not provide the required data we will contact the authors to request it.

Secondary outcomes
We will assess the outcomes below, as measured by the diagnostic classification system or diagnostic tool used for the primary outcome, providing the data are available separately. When data are available, we will compile and provide a narrative description of the results.
1. Social communication.
2. Restricted and repetitive behaviour.

We have included these two secondary outcomes in consideration of the reorientation toward RDoC, with future studies likely to report on diagnostic outcomes in more dimensional ways. We will group outcome data into three time periods for analysis purposes: short-term (up to 2 years), medium-term (2 to 5 years) and long-term follow-up (6 to 17 years).
We will include all outcomes in a ‘GRADE Evidence Profile’ table.

Search method for identification of studies
We will search the following electronic databases:
1. MEDLINE Ovid (1946 to current);
2. MEDLINE In-Process & Other Non-Indexed Citations Ovid (current issue);
3. MEDLINE Epup Ahead of Print Ovid (current issue);
4. Embase Ovid (1980 to current);
5. CINAHL Plus EBSCOhost (Cumulative Index to Nursing and Allied Health Literature; 1937 to current);
6. PsycINFO Ovid (1967 to current);
Two review authors (AB, NA-U, SW or KW) will independently screen records by title and abstract, removing those that are clearly irrelevant (do not meet the criteria listed above). We will advance records that have collected information on diagnosis of autism spectrum disorder, followed individuals for 12 months or more and have a sample size of more than 10 to the next stage. We will then obtain the full text of potentially relevant reports, including those where we consider inclusion criteria to be unclear, for review and, where appropriate, data extraction. At this stage, we will screen reports for type of diagnostic assessment tool used, whether diagnosis was made at baseline or prior to the start of the study and whether cut-offs for autism spectrum disorder were met on the assessment tools. Disagreements will be resolved by discussion. If the disagreement cannot be resolved a third review author, who was not one of the two initial assessors, will act as an arbiter. The types of data likely to be reported in studies include numbers, percentages and/or survival curves.

Assessment of risk of bias in included studies

Two review authors will independently assess the risk of bias in each report by examining study participation, study attrition and outcome measurement. They will code studies as at high, medium, low or unclear risk of bias for each of these features. We have modified this approach from current literature that addresses the assessment of quality in prognostic systematic reviews (Hayden 2006; Hayden 2013). Details regarding the coding of risk of bias are provided in Appendix 3. Each of the three main domains in the ‘Risk of bias’ assessment (study participation, study attrition and outcome measurement) include items that are rated on a scale of low, medium to high risk of bias. We will combine these ratings to provide an overall ‘Risk of bias’ rating for each domain and one overall ‘Risk of bias’ rating for the study. We will group studies at medium and low risk of bias for sensitivity analysis. As we are not assessing prognostic factors (predictors of outcome) in this review, we will not conduct an analysis of confounders.

If the information required to make an assessment of risk of bias is not available, or it is not possible to extract information about other variables required for sensitivity analyses, we will email the authors of studies published after 2010 to ask for further information, as done in a previous review (see Woolfenden 2012). If the study authors are unwilling or unable to give us additional information, we will document that we have attempted to contact the study authors and mark the risk of bias as unclear. If the minimum necessary information required for inclusion is not available, we will exclude the study from the relevant analyses. We will use ‘Risk of bias’ assessments to assess the quality of included studies and for sensitivity analyses.

Measures of association

We will not extract measures of association as we are not analysing prognostic factors in this review.
Unit of analysis issues
We will collect and analyse study level data from studies included in this review. Some studies may use relevant characteristics as eligibility criteria and, as such, report them at the study level; for example, intelligence, age of participants and duration of follow-up. We will extract the number of individuals with and without a diagnosis of autism spectrum disorder at the time of follow-up and calculate the percentage, if not presented in the paper. We will also extract these data for subgroup analysis, if presented in this way. The only likely data manipulation we will carry out will be if continuous scores rather than dichotomised categories are presented for diagnostic groups, as described above. If studies have reported data for subgroups (e.g. autistic or autism spectrum disorder; male or female) we will calculate a composite mean score, if this is meaningful. We will do this by conducting a fixed-effect meta-analysis of within-study groups, following the methods described by Borenstein 2009. Individual participant data meta-analyses are outside the scope of this review.

Dealing with missing data
We will include studies that follow up individuals with autism spectrum disorder for one or more years after entry, and report the proportion who still have the same diagnosis at follow-up, even if there are missing data. We will contact study authors to obtain further information on missing data, when necessary. We will describe the missing data in the ‘Risk of bias’ tables and consider the extent to which these may have impacted the results of our review. We will assess the sensitivity of any primary analyses to missing data using the strategy described in the Cochrane Handbook for Systematic Reviews of Interventions (Deeks 2011). If authors are unwilling or unable to provide additional information on missing data we will analyse only available data. We will not impute missing data as children with autism spectrum disorder are very heterogeneous. We will document missing data and discuss the possible impact of missing data on each study, in terms of risk of bias, and on the overall review, in terms of quality of evidence.

Assessment of heterogeneity
We will assess clinical heterogeneity by comparing important participant factors at a study level, and methodological heterogeneity by comparing the risk of bias of studies, taking into account study participation, participant attrition and outcome measurement factors across the studies (see Appendix 3). We will assess statistical heterogeneity by inspecting forest plots, and will use the I^2 and Tau^2 statistics to estimate the total variation across studies due to heterogeneity. If we find high levels of heterogeneity (I^2 > 50%) for the primary outcome, we will explore possible sources of heterogeneity using the subgroup and sensitivity analyses described below, as required by our secondary objectives.

Reporting bias
If we are able to pool 10 or more studies, we will examine publication bias and other small study effects, using a funnel plot in Review Manager (RevMan), version 5 (Review Manager 2014). We will check for asymmetry at a 10% level. We will attempt to obtain the results of unpublished studies by contacting study authors. Where this is not possible, and the missing studies are thought to introduce significant bias, we will explore the impact of including such studies in the overall assessment of results using sensitivity analyses.

Data synthesis
Since there is a high likelihood of heterogeneity in this population, we plan to pool the available data using a random-effects model. If the studies are found to be more homogeneous than expected, we will also use the study data using a fixed-effect model. We will use Review Manager 2014 to pool data, perform statistical analyses and generate forest plots, if it is appropriate to combine results. We will conduct meta-analyses if data are available from three or more sufficiently homogeneous studies. We will use a random-effects, generic inverse variance meta-analysis model in Review Manager 2014. We will summarise the meta-analysis using the pooled estimate, its 95% confidence interval, and the estimate of between-study variance using Tau^2.

If it is not appropriate to combine results using meta-analysis (in the case of heterogeneity or a small number of studies), we will provide a narrative description of the results. We will use an approach modified from the GRADE framework (Iorio 2015). We will judge and report the overall quality of evidence for all our outcomes using this modified GRADE approach. We will rate the overall strength of evidence considering risk of bias, inconsistency, indirectness, imprecision, publication bias, effect size, dose-response gradient (see Appendix 4). We will rank evidence as high, moderate, low or very low (see Appendix 5). We will collect information in a ‘GRADE Evidence Profile’ table (Schünemann 2013; see Appendix 6).

Subgroup and sensitivity analysis

Subgroup analysis
There are a number of potential sources of heterogeneity in studies in individuals with autism spectrum disorder, such as the use of different tools or classification systems to diagnose autism spectrum disorder, different classification systems and types of participants (e.g. with or without language delay or intellectual disability; level of adaptive behaviour). We will assess the primary outcome only in subgroup analyses. We will examine differences between participant subgroups by visual inspections of confidence intervals for:
1. age at baseline: < 2 years; 2 to 3 years; 4 to 6 years; 7 to 12 years; 13 to 17 years;
2. age at follow up: 2 to 3 years; 4 to 6 years; 7 to 12 years; 13 to 18 years;
3. duration of follow-up: short-term (up to 2 years), medium-term (2 to 5 years), and long-term (6 to 17 years) follow-up;
5. intelligence: mean IQ \( \leq 70 \); mean IQ > 70; or more than 70% of the cohort has IQ \( \leq 70 \);
6. studies that use the same version of the diagnostic tool or a different version of the diagnostic tool at baseline and follow-up (e.g. ADOS (Lord 2000) and ADOS-2 (Lord 2012));
7. type of diagnostic approach at baseline: multidisciplinary or not multidisciplinary;
8. adaptive behaviour: mean standard score \( \leq 70 \); mean standard score > 70; or > 70% of the cohort has mean standard score \( \leq 70 \);
9. language: > 70% verbal; > 70% non-verbal (i.e. use < 15 words); mean standardised language score \( < 70 \); mean standardised language score \( \geq 70 \); or > 70% of the cohort has mean language score \( < 70 \); and
10. diagnostic subgroups: autistic disorder or childhood autism compared with other autism spectrum disorders, including Asperger’s syndrome/disorder; atypical autism; and PDD-NOS.

We will accept non-overlapping confidence intervals to indicate a statistically significant difference between subgroups. We will conduct analyses using Review Manager 2014.

**Sensitivity analysis**

We will use sensitivity analyses to assess the impact of our decisions made during the review (e.g. inclusion of studies in the review and risk of bias of studies, taking into account recruitment, blinding and outcome measurement factors). This will be achieved by repeating the analyses using an alternative method or assumption, in order to explore the influence of our ’Risk of bias’ assessments; for example, by the exclusion of lower-quality studies (those at high or unclear risk of bias due to study participation, participant attrition or outcome measurement).

**ACKNOWLEDGEMENTS**

We would like to thank the universities and hospitals that employ us and support our engagement in this work. We would also like to thank the editorial team of Cochrane Developmental, Psychosocial and Learning Problems for their advice and support during the preparation of this protocol, particularly Margaret Anderson who contributed to the development of the search strategy, and the editors, external referees and statistician who commented on earlier drafts.

**REFERENCES**

Additional references

APA 1980

APA 1994

APA 2000

APA 2013

Barbaro 2016

Beuscher 2014

Borenstein 2009

CDC 2014

Corsello 2013
Overall prognosis of preschool autism spectrum disorder diagnoses (Protocol)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.


Guyatt 2011

Hansen 2015

Hayden 2006

Hayden 2013

Hayden 2014

Horlin 2014

Howlin 2004

Howlin 2012

Iorio 2015

Jónsdóttir 2007


NCHS 2011

NICE 2011

Orinstein 2014

Ozonoff 2015

Review Manager 2014 [Computer program]

Rondeau 2010

Schopler 1980

Schünemann 2013

Simonoff 2008
Skuse 2004

Takeda 2005

Turner 2007

Volkmar 2014

WAADF 2012

WHO 1979

WHO 1992

Wing 2002a

Wing 2002b

Woolfenden 2012

* Indicates the major publication for the study

APPENDICES

Appendix 1. Ovid MEDLINE search strategy
1 child development disorders, pervasive/
2 asperger syndrome/
3 autism spectrum disorder/
4 autistic disorder/
5 autis$.tw
6 asperger$.tw.
7 pervasive development$.disorder$.tw.
8 (child$ adj3 pervasive$).tw.
9 (PDD adj3 (specified or unspecified)).tw.
10 PDD-NOS.tw.
11 or/1-10
12 prognosis/
13 prognos$.rw.
14 prevalence/

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
15 prevalence$.tw.
16 follow up studies/
17 (follow$ up$ or followup$).tw.
18 (diagnos$ adj3 (change$ or stable or unstable or stabil#e$ or stability or instability or re-evaluat$)).tw.
19 (diagnos$ adj3 (early or earlier or first or initial$ or original$ or previous$)).ab.
20 (diagnos$ adj3 (second or later or subsequent$)).ab.
21 (outcome$ adj3 (change$ or improve$ or worse or worst or worsen$)).tw.
22 (symptom$ adj3 (change$ or improve$ or reduc$ or severity or worse or worst or worsen$)).tw.
23 (measure$ adj3 (change$ or improve$ or worse or worst or worsen$)).tw.
24 predict$.ab.
25 or/12-24
26 11 and 25

### Appendix 2. Data collection spreadsheet

<table>
<thead>
<tr>
<th>Column heading</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study number</td>
<td>-</td>
</tr>
<tr>
<td>Author</td>
<td>First author (surname and first initial)</td>
</tr>
<tr>
<td>Year of publication</td>
<td>-</td>
</tr>
<tr>
<td>Description of study</td>
<td>Study description, prospective cohort, retrospective cohort, cross-sectional cohort, assessment of outcome, assessment of predictive factors, analysis or discussion of confounders, controlled, with/without intervention</td>
</tr>
<tr>
<td>Groups</td>
<td>Control group versus intervention group</td>
</tr>
<tr>
<td>Inclusion/exclusion criteria</td>
<td>Participants that were eligible for study</td>
</tr>
<tr>
<td>Study population/group</td>
<td>Clinic versus population versus community</td>
</tr>
<tr>
<td>Size of population/group</td>
<td>Number (N), denominator for proportion analyses</td>
</tr>
<tr>
<td>Interventions</td>
<td>Type and amount of interventions</td>
</tr>
<tr>
<td>Diagnostic criteria</td>
<td>DSM; ICD; or Kanner</td>
</tr>
<tr>
<td>Diagnostic tool/measure</td>
<td>ADI-R; ADOS; CARS; GARS; 3di; or DISCO</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>AD; ASD; AD + PDD-NOS; as defined by diagnostic criteria</td>
</tr>
<tr>
<td>Timing of diagnosis</td>
<td>Prior to study, at baseline, etc.</td>
</tr>
<tr>
<td>Study attrition</td>
<td>Number of participants lost to follow-up; participants that did not complete all parts of follow-up</td>
</tr>
</tbody>
</table>
### Study approach and outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Measure used</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cognitive ability/IQ</td>
<td>Outcome; measure used</td>
</tr>
<tr>
<td>Autistic symptoms - core</td>
<td>Outcome: social communication/repetitive, restricted behaviours, and interests; measure used</td>
</tr>
<tr>
<td>Autistic symptoms - other</td>
<td>Outcome: what symptoms or measure used</td>
</tr>
<tr>
<td>Change in diagnosis</td>
<td>Outcome: measure and criteria used</td>
</tr>
<tr>
<td>Other</td>
<td>Which outcome or measure used</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Period of follow-up in years</th>
<th>Length of follow-up for the study</th>
</tr>
</thead>
</table>

| Notes | - |

### Footnotes

AD: autistic disorder; ADI-R: Autism Diagnostic Interview - Revised; ADOS: Autism Diagnostic Observation Schedule; ASD: autism spectrum disorder; CARS: Childhood Autism Rating Scale; DISCO: Diagnostic Interview for Social and Communication Disorders; DSM: Diagnostic and Statistical Manual of Mental Disorders; GARS: Gilliam Autism Rating Scale; ICD: International Classification of Diseases; IQ: intelligence quotient; PDD-NOS: pervasive developmental disorder-not otherwise specified; 3di: developmental, dimensional and diagnostic interview.

### Appendix 3. 'Risk of bias' table

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Unclear</th>
<th>High</th>
<th>Medium</th>
<th>Low</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample (described)</td>
<td>-</td>
<td>Clinical (not community based)</td>
<td>Clinical but drawn from broad community base</td>
<td>Population based</td>
</tr>
<tr>
<td>Description of sampling frame</td>
<td>-</td>
<td>Not described</td>
<td>Some description but not adequate or complete</td>
<td>Well described</td>
</tr>
<tr>
<td>Description of baseline study sample</td>
<td>-</td>
<td>Not described</td>
<td>Some description but not adequate or complete</td>
<td>Well described</td>
</tr>
<tr>
<td>Description of inclusion or exclusion criteria</td>
<td>-</td>
<td>Not described</td>
<td>Some description but not adequate or complete</td>
<td>Well described</td>
</tr>
<tr>
<td>Adequacy of participation in study by all eligible</td>
<td>-</td>
<td>No</td>
<td>-</td>
<td>Yes</td>
</tr>
</tbody>
</table>
### 2. Study attrition: the study data available (those not lost to follow-up) adequately represent the study sample

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Unclear</th>
<th>High</th>
<th>Medium</th>
<th>Low</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recruitment</td>
<td>-</td>
<td>Retrospective</td>
<td>Retrospective with whole cohort considered</td>
<td>Prospective</td>
</tr>
<tr>
<td>LFU (%)</td>
<td>-</td>
<td>&lt; 80% remain</td>
<td>≥ 80% remain</td>
<td>≥ 85% remain</td>
</tr>
<tr>
<td>Description of attempts to collect information on those LFU</td>
<td>-</td>
<td>No</td>
<td>Some information provided but not adequate</td>
<td>Yes</td>
</tr>
<tr>
<td>Reasons for LFU provided?</td>
<td>-</td>
<td>No</td>
<td>Some information provided but not adequate</td>
<td>Yes</td>
</tr>
<tr>
<td>Reasons for LFU linked to outcome?</td>
<td>-</td>
<td>No</td>
<td>Some information provided but not adequate</td>
<td>Yes</td>
</tr>
<tr>
<td>Adequate description of LFU participants?</td>
<td>-</td>
<td>No</td>
<td>Some information provided but not adequate</td>
<td>Yes</td>
</tr>
<tr>
<td>Analysis: important differences between LFU and non-LFU in study?</td>
<td>-</td>
<td>Important differences</td>
<td>-</td>
<td>No important differences</td>
</tr>
</tbody>
</table>

### 3. Outcome measurement: the outcomes of interest are measured in a similar way for all participants

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Unclear</th>
<th>High</th>
<th>Medium</th>
<th>Low</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding</td>
<td>-</td>
<td>Not blinded</td>
<td>Blinding inadequate</td>
<td>Blinding adequate</td>
</tr>
<tr>
<td>Clear definition of outcome provided?</td>
<td>-</td>
<td>No</td>
<td>-</td>
<td>Yes</td>
</tr>
<tr>
<td>Same outcome tool for all?</td>
<td>-</td>
<td>Not same tool for all</td>
<td>-</td>
<td>Same for all</td>
</tr>
<tr>
<td>Valid and reliable tool?</td>
<td>-</td>
<td>Not valid, reliable tool used</td>
<td>Valid or reliable tool, but parent rating</td>
<td>Standardised, reliable, valid tool used</td>
</tr>
<tr>
<td>Method and setting of outcome measurement same for all participants?</td>
<td>-</td>
<td>No</td>
<td>-</td>
<td>Yes</td>
</tr>
<tr>
<td>Completeness of outcome measure</td>
<td>-</td>
<td>Not all tools completed (&gt; 90% missing)</td>
<td>Not all tools completed but not &gt; 90% missing</td>
<td>All tools completed</td>
</tr>
</tbody>
</table>
### Appendix 4. GRADE assessment for judging the overall quality of the evidence for prognosis

Starting grade:  
HIGH: Observational Study  
LOW: Randomised Controlled Trial

<table>
<thead>
<tr>
<th>Domain</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade down if:</td>
<td>Risk of bias: Most evidence is from studies with moderate or high risk of bias for most risk of bias domains</td>
</tr>
<tr>
<td></td>
<td>Inconsistency: Unexplained heterogeneity or variability in results (point estimates) across studies with differences in results that are not clinically meaningful</td>
</tr>
</tbody>
</table>
|                 | Meta-analysis: large $I^2$ value (significant heterogeneity)  
|                 | Narrative analysis: variations in estimates across studies with points of effect on either side of the lines of no effect and confidence intervals showing little overlap |
|                 | Indirectness: The study sample or the outcomes in the study, or both, do not accurately reflect the population of interest or the measured outcome does not capture what is believed to be important |
|                 | Imprecision: This is based on the width of the 95% confidence interval around the pooled estimate/effect size (meta-analysis) and the position of the confidence interval relative to clinical decision threshold. That is, there is no precise estimate of the effect size in the meta-analysis and confidence intervals are excessively wide or they overlap with the value of no effect.  
|                 | In narrative analyses, there is no precision in the estimation of the effect size within each study. Also graded down if there is across study imprecision: few studies and insufficient sample size (< 100 cases reaching follow-up) or no justification provided for small sample size |
|                 | Publication bias: Confidence downgraded unless specific outcomes have been repeatedly investigated |
| Grade up if:    | Large effect: Moderate or large effect reported by most studies or in pooled findings in the meta-analysis |
|                 | Dose-response gradient: Gradient exists between studies for factors measured at different doses or an increase or decrease in events over time, which follows a well-defined pattern (e.g. linear) |

*Footnotes*  
Table modified from [Guyatt 2011](#), [Hayden 2014](#) and [Iorio 2015](#).
Appendix 5. Levels of quality

<table>
<thead>
<tr>
<th>Quality level</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>Very confident that the true prognosis lies close to that of the estimate</td>
</tr>
<tr>
<td>Moderate</td>
<td>Moderately confident that the true prognosis is likely to be close to the estimate, but there is a possibility that it is substantially different</td>
</tr>
<tr>
<td>Low</td>
<td>Confidence in the estimate is limited. True prognosis may be substantially different from the estimate</td>
</tr>
<tr>
<td>Very low</td>
<td>We have very little confidence in the estimate. True prognosis is likely to be substantially different from the estimate</td>
</tr>
</tbody>
</table>

Footnotes
Taken from Iorio 2015.

Appendix 6. 'GRADE Evidence Profile' table

<table>
<thead>
<tr>
<th>Quality assessment</th>
<th>Effect</th>
<th>Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of studies (Study design)</td>
<td>Risk bias of Inconsistency Indirectness Imprecision Other considerations No. of events No. of individuals Rate (95% CI)</td>
<td></td>
</tr>
<tr>
<td>New outcome 1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>New outcome 2</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Footnotes
CI: Confidence interval; No.: Number
WHAT'S NEW

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>31 August 2017</td>
<td>Amended</td>
<td>Updating author's (AI) declaration of interest. See Declarations of interest.</td>
</tr>
</tbody>
</table>

CONTRIBUTIONS OF AUTHORS

Drafting the protocol: AB, NA-U, SW, AI, KW.
Developing a search strategy: AB, SW, KW.
Final approval of protocol: all authors.
AB is the guarantor for the review.

DECLARATIONS OF INTEREST

Amanda Brignell was employed by the University of Melbourne as a Research Assistant, which was funded by the William Collie Trust, while she was writing this protocol. She also received an Australian Post Graduate Award for her PhD. During the time of this protocol, Amanda was completing a systematic review on language outcomes for autism spectrum disorder, as well as conducting a study looking at communication trajectories in children with autism spectrum disorder. Amanda will not assess the eligibility or extract data from any studies that she is involved in should they appear in the searches for this review.

Natalia Albein-Urios - none known.
Susan Woolfenden - none known.
Andrew Hayen - none known.

Alfonso Iorio's institution has received project based funding via research or service agreements with Bayer, Grifols, NovoNordisk, Pfizer and Shire (formerly Baxter and Baxalta).

Katrina Williams is an Editor with Cochrane Developmental, Psychosocial and Learning Problems. Katrina's appointment as the APEX Australia Chair of Developmental Medicine at the University of Melbourne is funded from donations made to the The Royal Children's Hospital Foundation, with the major donor being the Apex Foundation for Research into Intellectual Disability.

SOURCES OF SUPPORT

Internal sources

- The William Collie Trust, Australia.
The trust supports staff working on this review.
External sources

- None, Other.